Home > Insider Trading > Filing (0001181431-14-029544)

Filing Details

Accession Number:: 0001181431-14-029544
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-08-18 17:46:43
Reporting Period:: 2014-08-14

Filing Date:: 2014-08-18
Accepted Time:: 2014-08-18 17:46:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1571498	Epizyme Inc.	EPZM	Pharmaceutical Preparations (2834)	261349956

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1302106	D Ryan Drant	1954 Greenspring Drive Suite 600 Timonium MD 21093		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-08-14	1,290,000	$0.00	4,743,240	No	4	J	Indirect	See Note 2
Common Stock	Acquisiton	2014-08-14	12,900	$0.00	12,900	No	4	J	Indirect	See Note 4
Common Stock	Disposition	2014-08-14	12,900	$0.00	0	No	4	J	Indirect	See Note 4
Common Stock	Acquisiton	2014-08-14	3,411	$0.00	3,411	No	4	J	Indirect	See Note 7
Common Stock	Disposition	2014-08-15	3,027	$36.45	384	No	4	S	Indirect	See Note 7
Common Stock	Disposition	2014-08-15	384	$36.94	0	No	4	S	Indirect	See Note 7
Common Stock	Acquisiton	2014-08-14	455	$0.00	455	No	4	J	Direct
Common Stock	Disposition	2014-08-15	455	$36.72	0	No	4	S	Direct
Common Stock	Acquisiton	2014-08-14	195	$0.00	195	No	4	J	Indirect	See Note 12
Common Stock	Disposition	2014-08-15	195	$36.70	0	No	4	S	Indirect	See Note 12

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	J	Indirect	See Note 2
No	4	J	Indirect	See Note 4
No	4	J	Indirect	See Note 4
No	4	J	Indirect	See Note 7
No	4	S	Indirect	See Note 7
No	4	S	Indirect	See Note 7
No	4	J	Direct
No	4	S	Direct
No	4	J	Indirect	See Note 12
No	4	S	Indirect	See Note 12

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	406,500	Indirect	See Note 13

Footnotes

New Enterprise Associates 13, L.P. ("NEA 13") made a pro rata distribution for no consideration of an aggregate of 1,290,000 shares of Common Stock of the Issuer, to its general partner and its limited partners on August 14, 2014.
The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of NEA 13, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 shares in which the Reporting Person has no pecuniary interest.
NEA Partners 13 received 12,900 shares of Common Stock of the Issuer in the distribution by NEA 13 on August 14, 2014.
The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, the director beneficial owner of the shares of Common Stock of the Issuer. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA Partners 13 shares in which the Reporting Person has no pecuniary interest.
NEA Partners 13 made a pro rata distribution for no consideration of an aggregate of 12,900 shares of Common Stock of the Issuer to its limited partners on August 14, 2014.
New Enterprise Associates, LLC ("NEA LLC") received 3,411 shares of Common Stock of the Issuer in the distribution by NEA Partners 13 on August 14, 2014.
The Reporting Person is a member of the Board of Directors of NEA LLC, which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares of the Issuer held by NEA LLC in which the Reporting Person has no pecuniary interest.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.74 to $36.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (8) to this Form 4.
The Reporting Person received 455 shares of Common Stock of the Issuer in the distribution by NEA Partners 13 on August 14, 2014.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.69 to $36.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (10) to this Form 4.
The Ryan Drant 2006 Family Trust received 195 shares of Common Stock of the Issuer in the distribution by NEA Partners 13 on August 14, 2014.
The securities are directly held by the Ryan Drant 2006 Family Trust. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities of the Issuer held by the Ryan Drant 2006 Family Trust in which the Reporting Person has no pecuniary interest.
The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13. NEA Partners 13 is the sole general partner of NEA 13, which is the sole member of Growth Equity Opportunities Fund II, LLC ("GEO II"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the GEO II shares in which the Reporting Person has no pecuniary interest.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.74 to $37.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (14) to this Form 4.